Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.

Shah, Chintan; Hong, Young-Rock; Bishnoi, Rohit; Ali, Azka; Skelton, William Paul; Dang, Long H; Huo, Jinhai; Dang, Nam H

Shah, Chintan; Hong, Young-Rock; Bishnoi, Rohit; Ali, Azka; Skelton, William Paul; Dang, Long H; Huo, Jinhai; Dang, Nam H.

Afiliação

Shah C; Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, United States.
Hong YR; Department of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States.
Bishnoi R; Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, United States.
Ali A; Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, United States.
Skelton WP; Division of Medical Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, United States.
Dang LH; Ochsner Medical Center, Baton Rouge, LA, United States.
Huo J; Department of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States.
Dang NH; Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, United States.

Front Oncol ; 10: 405, 2020.

Article em En | MEDLINE | ID: mdl-32296640

Palavras-chave

DPP4 (Dipeptidyl peptidase 4) inhibitors; Januvia; breast; cancer; pancreas; prostate; sitagliptin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google